Compare Stocks

→ Could Bitcoin Literally FORCE This Crypto To Rocket Up? (From Paradigm Press) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MYMD MyMD Pharmaceuticals	$2.25 +7.1%	$2.98	$2.00 ▼ $70.50	$4.53M	2.29	200,323 shs	45,305 shs
NYMX Nymox Pharmaceutical		$0.34	$0.17 ▼ $0.74	$18.10M	0.64	94,622 shs	932,700 shs
VNRX VolitionRx	$0.60 -3.2%	$0.89	$0.55 ▼ $2.10	$50.88M	1.35	155,723 shs	172,749 shs
VNRX VolitionRx	$0.60 -3.2%	$0.89	$0.55 ▼ $2.10	$50.88M	1.35	155,723 shs	172,749 shs

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MYMD MyMD Pharmaceuticals	+7.14%	-18.18%	-20.77%	-59.89%	-95.00%
NYMX Nymox Pharmaceutical	0.00%	0.00%	0.00%	0.00%	-52.14%
VNRX VolitionRx	-2.44%	-16.91%	-31.21%	-38.14%	+59,999,900.00%
VNRX VolitionRx	-2.44%	-16.91%	-31.21%	-38.14%	+59,999,900.00%

Could Bitcoin Literally FORCE This Crypto To Rocket Up? (Ad)

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
MYMD MyMD Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NYMX Nymox Pharmaceutical	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VNRX VolitionRx	1.3389 of 5 stars	3.5	0.0	0.0	0.0	3.3	0.8	0.0
VNRX VolitionRx	1.3389 of 5 stars	3.5	0.0	0.0	0.0	3.3	0.8	0.0

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MYMD MyMD Pharmaceuticals	N/A	N/A	N/A	N/A
NYMX Nymox Pharmaceutical	N/A	N/A	N/A	N/A
VNRX VolitionRx	3.00	Buy	$2.50	316.67% Upside
VNRX VolitionRx	3.00	Buy	$2.50	316.67% Upside

Current Analyst Ratings

Latest NYMX, MYMD, VNRX, and VNRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
3/27/2024	VNRX VolitionRx	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$2.50
3/27/2024	VNRX VolitionRx	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$2.50

(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MYMD MyMD Pharmaceuticals	N/A	N/A	N/A	N/A	$7.21 per share	N/A
NYMX Nymox Pharmaceutical	N/A	N/A	N/A	N/A	($0.01) per share	N/A
VNRX VolitionRx	$770K	63.95	N/A	N/A	($0.11) per share	-5.45
VNRX VolitionRx	$770K	63.95	N/A	N/A	($0.11) per share	-5.45

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MYMD MyMD Pharmaceuticals	-$4M	-$5.41	N/A	∞	N/A	N/A	-103.16%	-56.50%	5/20/2024 (Estimated)
NYMX Nymox Pharmaceutical	-$6.58M	-$0.04	N/A	N/A	N/A	N/A	-1,589.50%	-117.25%	N/A
VNRX VolitionRx	-$35.32M	-$0.51	N/A	∞	N/A	-4,557.29%	N/A	-154.24%	5/8/2024 (Estimated)
VNRX VolitionRx	-$35.32M	-$0.51	N/A	∞	N/A	-4,557.29%	N/A	-154.24%	5/8/2024 (Estimated)

Latest NYMX, MYMD, VNRX, and VNRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/25/2024	N/A	VNRX VolitionRx	N/A	-$0.11	-$0.11	-$0.11	$0.50 million	$0.24 million
3/25/2024	N/A	VNRX VolitionRx	N/A	-$0.11	-$0.11	-$0.11	$0.50 million	$0.24 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
MYMD MyMD Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NYMX Nymox Pharmaceutical	N/A	N/A	N/A	N/A	N/A
VNRX VolitionRx	N/A	N/A	N/A	N/A	N/A
VNRX VolitionRx	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MYMD MyMD Pharmaceuticals	N/A	1.17	1.17
NYMX Nymox Pharmaceutical	N/A	0.19	0.19
VNRX VolitionRx	N/A	0.69	0.69
VNRX VolitionRx	N/A	0.69	0.69

Ownership

Institutional Ownership

Company	Institutional Ownership
MYMD MyMD Pharmaceuticals	9.64%
NYMX Nymox Pharmaceutical	1.14%
VNRX VolitionRx	8.09%
VNRX VolitionRx	8.09%

Insider Ownership

Company	Insider Ownership
MYMD MyMD Pharmaceuticals	2.63%
NYMX Nymox Pharmaceutical	54.00%
VNRX VolitionRx	15.40%
VNRX VolitionRx	15.40%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
MYMD MyMD Pharmaceuticals	10	2.16 million	2.10 million	Optionable
NYMX Nymox Pharmaceutical	3	90.51 million	41.64 million	Optionable
VNRX VolitionRx	110	82.07 million	69.43 million	Optionable
VNRX VolitionRx	110	82.07 million	69.43 million	Optionable

NYMX, MYMD, VNRX, and VNRX Headlines

Source	Headline
	VolitionRx (NYSE:VNRX) Now Covered by StockNews.com americanbankingnews.com - April 18 at 2:24 AM
	Zacks Small Cap Comments on VolitionRx Limited's FY2024 Earnings (NYSE:VNRX) americanbankingnews.com - April 11 at 2:40 AM
	Critical Review: VolitionRx (NYSE:VNRX) vs. Global WholeHealth Partners (OTCMKTS:GWHP) americanbankingnews.com - April 11 at 2:02 AM
	Research Analysts Set Expectations for VolitionRx Limited's FY2024 Earnings (NYSE:VNRX) marketbeat.com - April 10 at 8:28 AM
	VolitionRx Limited (NYSE:VNRX) to Post Q1 2024 Earnings of ($0.11) Per Share, Zacks Small Cap Forecasts americanbankingnews.com - April 10 at 1:22 AM
	VolitionRx Limited Forecasted to Post Q1 2024 Earnings of ($0.11) Per Share (NYSE:VNRX) marketbeat.com - April 9 at 6:09 AM
	VNRX: VolitionRx Reports 2023 Results; Distribution of Nu.Q Vet Test Expanding; Nu.Q Discover Growing; Two Key R&D Efforts in 2024/25: 1) Breakthrough Cancer Detection Method ... msn.com - April 8 at 3:37 PM
	VNRX: VolitionRx Reports 2023 Results; Distribution of Nu.Q Vet Test Expanding; Nu.Q Discover Growing; Two Key R&D Efforts in 2024/25: 1) Breakthrough Cancer Detection Method (Capture -PCR) 2) Nu.Q NET for Sepsis finance.yahoo.com - April 8 at 3:37 PM
	VolitionRx's (VNRX) Overweight Rating Reiterated at Cantor Fitzgerald marketbeat.com - March 27 at 10:15 AM
	VolitionRx (NYSE:VNRX) Releases Earnings Results marketbeat.com - March 26 at 9:17 AM
	VNRX Stock Earnings: VolitionRX Meets EPS, Misses Revenue for Q4 2023 msn.com - March 25 at 9:15 PM
	VolitionRx Limited Announces Full Fiscal Year 2023 Financial Results and Business Update prnewswire.com - March 25 at 4:10 PM
	Earnings Outlook For VolitionRX benzinga.com - March 22 at 11:30 AM
	VolitionRx Limited Schedules Fourth Quarter and Full Year 2023 Earnings Conference Call and Business Update prnewswire.com - March 21 at 8:30 AM
	VolitionRx Limited: Volition appoints Dr Andrew Retter as Chief Medical Officer finanznachrichten.de - March 21 at 5:25 AM
	VolitionRx Names Andrew Retter Chief Medical Officer markets.businessinsider.com - March 19 at 11:18 PM
	Volition appoints Dr Andrew Retter as Chief Medical Officer finance.yahoo.com - March 19 at 6:17 PM
	VolitionRX Ltd money.usnews.com - March 19 at 8:16 AM
	VolitionRX Stock (AMEX:VNRX), Short Interest Report benzinga.com - February 22 at 10:12 PM
	VolitionRx stock soars after company discloses $13M in milestone payments msn.com - January 2 at 7:35 PM
	VolitionRx milestone payment 'important step forward,' says EF Hutton realmoney.thestreet.com - January 2 at 7:35 PM
	Analyzing VolitionRX Ltd (VNRX) After Recent Trading Activity knoxdaily.com - January 1 at 7:42 AM
	Volition Presents at the 5th Annual Congress of the International Liquid Biopsy Society finance.yahoo.com - November 17 at 1:08 PM
	VolitionRx to host Q3 earnings call on November 15 proactiveinvestors.com - November 8 at 2:08 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

MyMD Pharmaceuticals

NASDAQ:MYMD

MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the aging and age-related and autoimmune diseases, and chronic pain, anxiety, and sleep disorders. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system and its pro-inflammatory cytokines to prevent and treat autoimmune diseases and age-related illnesses, and a Phase 2 clinical trial for sarcopenia, multiple sclerosis, diabetes, inflammatory bowel diseases, and rheumatoid arthritis; inflammation related depression and anxiety; and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic analog of cannabidiol for treating epilepsy, pain, and anxiety/depression. The company was founded in 2014 and is headquartered in Baltimore, Maryland.

Nymox Pharmaceutical

NASDAQ:NYMX

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which is in various clinical trials for the treatment of benign prostatic hyperplasia and low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert for detecting tobacco product usage; and TobacAlert for detecting second-hand smoke exposure. In addition, it develops drugs for the treatment of Alzheimer's disease. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, the Bahamas.

VolitionRx

NYSE:VNRX

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening blood test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.

VolitionRx

NYSE:VNRX

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Price Performance

MarketRank™

Analyst Ratings

Current Analyst Ratings

Latest NYMX, MYMD, VNRX, and VNRX Analyst Ratings

Sales & Book Value

Profitability & Earnings

Latest NYMX, MYMD, VNRX, and VNRX Earnings

Dividends

Debt

Ownership

Institutional Ownership

Insider Ownership

Miscellaneous

NYMX, MYMD, VNRX, and VNRX Headlines

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

MyMD Pharmaceuticals

Nymox Pharmaceutical

VolitionRx

VolitionRx

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info